Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome

References

• Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–200.
   PubMed Web of Science ®Google Scholar
• Ozols RF. Advanced ovarian cancer: A clinical update on first-line treatment, recurrent disease, and new agents. J Natl Compr Canc Netw 2004;2(Suppl 2):S60–73.
   Google Scholar
• Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol 2007;35:185–97.
   PubMed Web of Science ®Google Scholar
• Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985;69:615–32.
   PubMedGoogle Scholar
• Larsson R, Nygren P. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model. Anticancer Res 1993;13:1825–9.
   PubMed Web of Science ®Google Scholar
• Nygren P, Fridborg H, Csoka K, Sundstrom C, de la Torre M, Kristensen J, et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 1994;56:715–20.
   PubMed Web of Science ®Google Scholar
• Larsson R, Nygren P, Ekberg M, Slater L. Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia 1990; 4:567–71.
   PubMed Web of Science ®Google Scholar
• Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992;50:177–85.
   PubMed Web of Science ®Google Scholar
• Jonsson E, Dhar S, Jonsson B, Nygren P, Graf W, Larsson R. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer 2000;36:2120–7.
   PubMed Web of Science ®Google Scholar
• Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 1994;54:163–70.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679–91.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Nelstrop AE, Crawford M, Ledermann J, Lambert HE, Coleman R, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172–6.
   PubMed Web of Science ®Google Scholar
• Fridborg H, Nygren P, Larsson R. Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Anticancer Drugs 1995;6:64–9.
   PubMed Web of Science ®Google Scholar
• Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009;8:543–8.
   PubMed Web of Science ®Google Scholar
• Malpica A. Grading of ovarian cancer: A histotype-specific approach. Int J Gynecol Pathol 2008;27:175–81.
   PubMed Web of Science ®Google Scholar
• Hess V, A’Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J Clin Oncol 2004;22:1040–4.
   PubMed Web of Science ®Google Scholar
• Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009;114:48–52.
   PubMed Web of Science ®Google Scholar
• Lee YY, Kim TJ, Kim MJ, Kim HJ, Song T, Kim MK, et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis. Gynecol Oncol 2011; 122:541–7.
   PubMed Web of Science ®Google Scholar
• Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99:653–8.
   PubMed Web of Science ®Google Scholar
• Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, et al. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 2009;125:2316–22.
   PubMed Web of Science ®Google Scholar
• Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL, 2nd, Shih IM, et al. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 2007;17:601–6.
   PubMed Web of Science ®Google Scholar
• McAlpine J, Eisenkop S, Spirtos N. Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol Oncol 2008;110:360–4.
   PubMed Web of Science ®Google Scholar
• Engblom P, Rantanen V, Kulmala J, Grenman S. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay. Anticancer Res 1996;16:1743–7.
   PubMed Web of Science ®Google Scholar
• Csoka K, Tholander B, Gerdin E, de la Torre M, Larsson R, Nygren P. In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1997;72:1008–12.
   PubMed Web of Science ®Google Scholar
• Gore ME, Preston N, A’Hern RP, Hill C, Mitchell P, Chang J, et al. Platinum-Taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer 1995;71:1308–10.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.
   PubMed Web of Science ®Google Scholar
• Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: A Gynecologic Oncology Group study. Cancer 2008;112:2202–10.
   PubMed Web of Science ®Google Scholar
• Trope C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: Review of the literature. J Clin Oncol 2007; 25:2909–20.
   PubMed Web of Science ®Google Scholar
• Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621–7.
   PubMed Web of Science ®Google Scholar
• Chi DS, Palayekar MJ, Sonoda Y, Abu-Rustum NR, Awtrey CS, Huh J, et al. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol 2008;108:191–4.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008;108:276–81.
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med 2008;5:e232.
   PubMed Web of Science ®Google Scholar
• Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Lele SB, Marchetti DL, et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 1998;70:392–7.
   PubMed Web of Science ®Google Scholar
• Konecny G. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000;77:258–63.
   PubMed Web of Science ®Google Scholar
• O’Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001;83:334–42.
   PubMed Web of Science ®Google Scholar
• Taylor CG, Sargent JM, Elgie AW, Williamson CJ, Lewandowicz GM, Chappatte O, et al. Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynaecol Oncol 2001;22:278–82.
   PubMed Web of Science ®Google Scholar
• Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 2002;87:8–16.
   PubMed Web of Science ®Google Scholar
• Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006;16:194–201.
   PubMed Web of Science ®Google Scholar
• Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician’s choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007;18:1093–101.
   PubMed Web of Science ®Google Scholar
• Karam AK, Chiang JW, Fung E, Nossov V, Karlan BY. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol 2009;114:246–52.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer 2009;125: 2721–7.
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 2010;203:68e1–6.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol 2010;116: 61–5.
   PubMed Web of Science ®Google Scholar
• Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2008;27:161–74.
   PubMed Web of Science ®Google Scholar